Skip to main content
Edinburgh BioQuarter
BioCentury on BioBusiness
Feature Story

Let a thousand ideas bloom

How Shire is breaking the mold to fuel external discovery in rare diseases

By Erin McCallister
Senior Writer 

Shire plc has long been a growth through acquisition company, but the pace of its external discovery is picking up steam and the company now has over 20 ongoing projects to show for it.

Traditional research collaborations are target- or MOA-driven, with the pharma or biotech supporting academic institutions that have a program focused on a particular disease-related gene or a novel disease pathway.

Full Article
BioCentury on BioBusiness
  • COVER STORY

    Paying for Procysbi

    Raptor is launching an ultra-Orphan drug it has shown is non-inferior to a cheaper alternative without having payers on board with the $250,000 price. It is banking on quality of life gains from better compliance.

  • STRATEGY

    Let a thousand ideas bloom

    Shire is paying collaborators to propose their best ideas for innovation in rare diseases, and is applying a similar open mind in its investment partnership with Atlas Ventures.

  • R&D rewind

    Shire's new CEO is consolidating R&D with the goal of broadening the company's reach in specialty pharma.

  • EMERGING COMPANY PROFILE

    Galileo: A TALL order

    Galileo's allogeneic immunotherapy mimics natural killer cells, but they spare healthy cells and could have broader activity than off-the-shelf cancer vaccines in development.

  • FINANCE

    Merck Serono's Earnest Money

    With fresh EUR 60 million from its pharma parent, MS Ventures aims to take an active role in its portfolio companies and expand from its early stage focus into selected later-stage opportunities.

  • Liquidity Preference

    Elan is betting its shareholders will like the return from investing $1 billion for a slice of Theravance's royalties, but Theravance shareholders signaled they liked the cash better.

  • Ebb & Flow

    PeptiDreams of an IPO in Japan. Amgen, Novartis: Partners less limited at Atlas. Vivus-First Manhattan. Also: Gilead-Infinity; Halozyme; Oncothyreon; Tesaro; Acadia; Aegerion; Ambit; Lexicon; Optimer, et al.

BioCentury TV

Science Booster Shot

SciBX on Science
  • COVER STORY

    Eritoran insight for influenza treatment

    A University of Maryland team has used a toll-like receptor 4 antagonist to treat influenza in mice. The results provide a repurposing opportunity for Eisai's TLR4 blocker Eritoran, originally developed for sepsis, and could extend to treating respiratory infections beyond the flu.

  • TARGETS & MECHANISMS

    Raising the Ras inhibitor bar

    About a year after U.S. researchers developed small molecule inhibitors of the intractable target wild-type Ras, a Japanese team has identified compounds that hit Ras mutant tumors in mice. The team now is trying to ramp up the potency of the compounds and make the structures more drug-like.

  • TOOLS

    CRISPR model building

    Boston researchers have used the CRISPR-Cas9 genome modification platform to simultaneously engineer mutations into multiple genes in mice. The results from the rapid, one-step process provide the best evidence to date for the potential of this method to revolutionize the creation of complex disease models.

  • Myelination gets direct

    Separate groups at Case Western and Stanford have developed approaches to directly reprogram rodent fibroblasts into oligodendrocyte progenitor cells. Although the method could be a safe and fast way to supply cells for myelination disorder cell therapies, the teams need to show that their methods also reprogram human fibroblasts.

  • THERAPEUTICS

    This Week in Therapeutics

    Enhancing IL-7 activity in autoimmune disease and antiviral immunity; improving immunotherapies for multiple myeloma with CEACAM6 inhibitors; preventing liver fibrosis with VDR agonists; and more...

  • TECHNIQUES

    This Week in Techniques

    Single-molecule analysis of epigenetic markers; bioluminescent mice to monitor progression of muscular dystrophy; use of CD49B and CD223 to isolate type 1 Treg cells; and more...
Subscribe Now
Free Trial
Keck Graduate Institute BioCentury eLearning

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

BioCentury This Week TV ChinaBio Today